- Home
- KD vs RNA Comparison
KD vs RNA Comparison
Compare KD & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KD
- RNA
- Stock Information
- Founded
- KD 2020
- RNA 2012
- Country
- KD United States
- RNA United States
- Employees
- KD N/A
- RNA N/A
- Industry
- KD EDP Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- KD Technology
- RNA Health Care
- Exchange
- KD Nasdaq
- RNA Nasdaq
- Market Cap
- KD 5.3B
- RNA 4.8B
- IPO Year
- KD N/A
- RNA 2020
- Fundamental
- Price
- KD $23.09
- RNA $41.58
- Analyst Decision
- KD Buy
- RNA Strong Buy
- Analyst Count
- KD 4
- RNA 7
- Target Price
- KD $30.25
- RNA $61.00
- AVG Volume (30 Days)
- KD 1.2M
- RNA 1.2M
- Earning Date
- KD 11-05-2024
- RNA 11-06-2024
- Dividend Yield
- KD N/A
- RNA N/A
- EPS Growth
- KD N/A
- RNA N/A
- EPS
- KD N/A
- RNA N/A
- Revenue
- KD $15,598,000,000.00
- RNA $10,599,000.00
- Revenue This Year
- KD N/A
- RNA $21.81
- Revenue Next Year
- KD $2.11
- RNA N/A
- P/E Ratio
- KD N/A
- RNA N/A
- Revenue Growth
- KD N/A
- RNA 8.15
- 52 Week Low
- KD $13.87
- RNA $4.83
- 52 Week High
- KD $28.60
- RNA $48.80
- Technical
- Relative Strength Index (RSI)
- KD 45.57
- RNA 48.74
- Support Level
- KD $22.37
- RNA $39.76
- Resistance Level
- KD $23.26
- RNA $42.00
- Average True Range (ATR)
- KD 0.56
- RNA 1.64
- MACD
- KD 0.05
- RNA -0.09
- Stochastic Oscillator
- KD 45.60
- RNA 47.96
About KD Kyndryl Holdings Inc.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.